<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[CNS]]></title><description><![CDATA[<p dir="auto">Anavex HISTORISKE OG BANEBRYDENDE RESULTATER I ALZHEIMER!!!</p>
<p dir="auto">Møder både primære og sekundære endpoints med stor signifikant!!</p>
<p dir="auto"></p><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">



<a href="https://anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints" title="Page not found | Anavex Life Sciences">
<img src="https://anavex.com/wp-content/uploads/2024/12/anavex-logo_dark.png" class="card-img-top not-responsive" style="max-height:15rem" alt="Link Preview Image" />
</a>





<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints">
Page not found | Anavex Life Sciences
</a>
</h5>
<p class="card-text line-clamp-3"></p>
</div>
<a href="https://anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://anavex.com/wp-content/uploads/2025/01/cropped-favicon-32x32.png" alt="favicon" class="not-responsive overflow-hiddden" style="max-width:21px;max-height:21px" />







<p class="d-inline-block text-truncate mb-0">Anavex Life Sciences <span class="text-secondary">(www.anavex.com)</span></p>
</a>
</div><p></p>
<p dir="auto">Disse resultater er endda bedre end man turde håbe på.</p>
<p dir="auto">Prof. Steve Macfarlane:<br />
"People living with Alzheimer's disease desperately need new therapies and I am truly impressed with the outcome of this study, which demonstrated reversal of cognitive decline," said A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. "These results complement and are consistent with findings from the previously completed Alzheimer's disease Phase 2a ANAVEX<img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/00ae.png?v=de222e39001" class="not-responsive emoji emoji-android emoji--registered" style="height:23px;width:auto;vertical-align:middle" title="®" alt="®" />2-73 trial, which also demonstrated therapeutic effect on cognition and function. ANAVEX<img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/00ae.png?v=de222e39001" class="not-responsive emoji emoji-android emoji--registered" style="height:23px;width:auto;vertical-align:middle" title="®" alt="®" />2-73 might be a very much needed solution for many patients with Alzheimer's disease."</p>
<p dir="auto">Tak for kampen herinde - vi vandt alligevel i sidste ende!</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/444541/cns</link><generator>RSS for Node</generator><lastBuildDate>Sun, 28 Jun 2026 06:40:05 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/444541.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 01 Dec 2022 23:58:13 GMT</pubDate><ttl>60</ttl></channel></rss>